WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009133463) SOLUBLE INFLUENZA VACCINE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/133463    International Application No.:    PCT/IB2009/005633
Publication Date: 05.11.2009 International Filing Date: 30.04.2009
Chapter 2 Demand Filed:    22.02.2010    
IPC:
C07K 14/11 (2006.01)
Applicants: UNIVERSITY OF COPENHAGEN [DK/DK]; (DK) (For All Designated States Except US).
HAKANSSON, Kjell, Ove [SE/SE]; (SE) (For US Only).
THOMSEN, Allan, Randrup [DK/DK]; (DK) (For US Only).
CHRISTENSEN, Jan, Pravsgaard [DK/DK]; (DK) (For US Only)
Inventors: HAKANSSON, Kjell, Ove; (SE).
THOMSEN, Allan, Randrup; (DK).
CHRISTENSEN, Jan, Pravsgaard; (DK)
Agent: KREMER, Simon, M.; Mewburn Ellis LLP 33 Gutter Lane London EC2V 8AS (GB)
Priority Data:
61/049,072 30.04.2008 US
Title (EN) SOLUBLE INFLUENZA VACCINE
(FR) VACCIN SOLUBLE CONTRE L'INFLUENZA
Abstract: front page image
(EN)The invention provides fusion proteins comprising: (i) a first portion comprising an influenza A M2e polypeptide, and (ii) a second portion comprising a rotaviral NSP4 polypeptide. The fusion proteins mimics the native tetrameric structure of native M2 protein. Additionally it is highly soluble and as disclosed herein can be produced and isolated in large quantities extremely quickly and efficiently. Also provided are related materials and methods, including use of the fusion proteins as vaccines.
(FR)La présente invention concerne des protéines de fusion comprenant les éléments suivants : (i) une première partie comportant un polypeptide A M2e de l'influenza, et (ii) une seconde partie comportant un polypeptide NSP4 de rotavirus. Les protéines de fusion imitent la structure tétramère native de la protéine M2 native. En outre, les protéines sont extrêmement solubles et, telles que présentées ici, peuvent être produites et isolées en grandes quantités très rapidement et efficacement. L'invention porte également sur des matériaux et des procédés afférents, y compris sur l'utilisation de protéines de fusion en tant que vaccins.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)